Mayo Clinic | Strategic Alliance Partners

Latest from Mayo Clinic


Dr. Bekaii-Saab on the Addition of Atezolizumab to Capecitabine/Bevacizumab in MSS mCRC

October 15, 2019

Tanios S. Bekaii-Saab, MD, FACP, discusses the results of the phase II BACCI trial evaluating the addition of atezolizumab to capecitabine plus bevacizumab versus capecitabine/bevacizumab plus placebo in patients with microsatellite stable metastatic colorectal cancer.

Dr. Bekaii-Saab on the Rationale to Evaluate Atezolizumab/Bevacizumab in MSS mCRC

October 05, 2019

Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses the rationale to evaluate atezolizumab (Tecentriq) and bevacizumab (Avastin) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

Dr. Bekaii-Saab on the APACT Trial in Pancreatic Cancer

September 30, 2019

Tanios S. Bekaii-Saab, MD, FACP, discusses the implications of the randomized phase III APACT trial evaluating gemcitabine alone versus gemcitabine plus nab-paclitaxel as adjuvant therapy in patients with pancreatic cancer.